Genomic Vision strengthens team
Appoints chief finance officer and vice president of research and development
Prior to joining Genomic Vision, Martin was cfo at Cytomics Pharmaceuticals (2003–2008), a biopharmaceutical company he co-founded with Dominique Thomas (Research Director at the CNRS Centre for Molecular Genetics, Gif-sur-Yvette) and for which he led the first rounds of financing. Prior to this he worked for 10 years as a consultant for Syndex, an auditing firm.
Conseiller joined Genomic Vision in 2009 after working for more than 17 years as a senior manager at sanofi-aventis (primarily within the oncology division). He is a pioneer in the application of functional genomics to drug discovery (from drug target screening to clinical trials) and has designed and led several projects for drug screening (small molecules and gene therapy) in the fields of tumour suppression, DNA replication and tumour metabolism. He holds a PhD from Pierre and Marie Curie University, Paris. In 1997, he won the Rhone-Poulenc Rorer Research Prize for his work on the development of chimeric tumour suppressors for gene therapy of cancer.
You may also like
Regulatory
MoonLake Immunotherapeutics faces Securities Class Action after disastrous Phase III trial results
The announcement about the trial results for the product candidate sonelokimab, a highly anticipated treatment for patients with skin disease, saw MoonLake investors' shares fall by about 90%, prompting an investigation into whether or not they were misled
Manufacturing
Roquette opens pharmaceutical innovation centre in Brazil
The Health & Pharma Solutions facility in São Paolo offers state-of-the-art laboratories for customers, with the Northeast Center for Strategic Technologies partnering with Roquette to empower young women to pursue careers in science through the Futuras Cientistas programme at the facility
Manufacturing
Samsung Bioepis and Phrontline join forces to advance best-in-class antibody-drug conjugate therapeutics for solid tumours
The pair will co-develop two investigational ADC assets directed against targets expressed in a broad range of cancers, adding a new class of bispecific and dual-payload ADC therapeutics to Samsung Bioepis' oncology portfolio
Research & Development
AlzeCure Pharma publishes response letter clarifying Alzstatin’s distinct mechanism in Alzheimer’s treatment
AlzeCure Pharma and leading academic collaborators have published a response in JPET addressing recent commentary on Alzstatin’s γ-secretase modulation data, reaffirming the promise of lead candidate ACD680 in Alzheimer’s therapy